Company intelligence / Profile preview

Endomag

Cambridge, England, United Kingdom

Ownership: Private
Development stage: Commercial

Overview

Endomag’s technologies—including the Sentimag platform, Magseed marker, and Magtrace tracer—are commercially available and have been used in over 500,000 procedures globally. Clinical studies demonstrate high accuracy in tumor localization and sentinel lymph node identification, reducing unnecessary surgeries and improving outcomes for breast cancer patients.

Therapeutic areas: Oncology
Modalities: DeviceNanoparticle
Industry: Surgical Medical Devices

Partnerships

Leica Biosystems (North America distribution)Sysmex Corporation (Europe distribution)Hologic (parent/distribution US & Canada)

Beyond the preview

Go deeper on Endomag.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endomag.

Explore the full profile